Anatomy of a discovery: M1 and M2 macrophages

Frontiers in Immunology

Volumn 6, Issue MAY, 2015, Pages

  Mills, Charles Dudley ^a  

^a BioMedical Consultants   (United States)

Author keywords

Cancer; Innate immunity; M1; M2; Macrophages; Th1 Th2; Wound

Indexed keywords

ARGINASE; ARGININE; CITRULLINE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MANNOSE RECEPTOR; NITRITE; ORNITHINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; CANCER IMMUNOLOGY; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL PROLIFERATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; HOST RESISTANCE; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PHENOTYPIC PLASTICITY; REVIEW; TH1 CELL; TH2 CELL; WOUND HEALING;

EID: 84934271896     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00212     Document Type: Review

References (84)

1. Mills CD, Ley K. M1 and M2 macrophages: the chicken and the egg of immunity. J Innate Immun (2014) 6:716-26. doi:10.1159/000364945
2. Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol (1989) 46:111-47. doi:10.1016/S0065-2776(08)60652-5
3. Scott P, Pearce E, Cheever AW, Coffman RL, Sher A. Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev (1989) 112:161-82. doi:10.1111/j.1600-065X.1989.tb00557.x
4. Finkelman FD, Holmes J, Katona IM, Urban JF Jr, Beckmann MP, Park LS, et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol (1990) 8:303-33. doi:10.1146/annurev.iy.08.040190.001511
5. O'Garra A, Murphy KM. Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol (1994) 6:458-66. doi:10.1016/0952-7915(94)90128-7
6. Hsieh CS, Macatonia SE, O'Garra A, Murphy KM. T cell genetic background determines default T helper phenotype development in vitro. J Exp Med (1995) 181:713-21. doi:10.1084/jem.181.2.713
7. Dzik JM. The ancestry and cumulative evolution of immune reactions. Acta Biochim Pol (2010) 57:443-66.
8. Buchmann K. Evolution of innate immunity: clues from invertebrates via fish to mammals. Front Immunol (2014) 5:459. doi:10.3389/fimmu.2014
9. Mills CD. M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol (2012) 32:463-88. doi:10.1159/000364945
10. Nathan CF. Secretory products of macrophages: twenty-five years on. J Clin Invest (2012) 122:1189-90. doi:10.1172/JCI62930
11. Currie GA, Gyure L, Cifuentes L. Microenvironmental arginine depletion by macrophages in vivo. Br J Cancer (1979) 6:613-20. doi:10.1038/bjc.1979.112
12. Hibbs JB, Vavrin Z, Taintor RR. l-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol (1987) 138:550-65.
13. Albina JE, Caldwell MS, Henry WL, Mills CD. Regulation of macrophage functions by l-arginine. J Exp Med (1989) 169:1021-9. doi:10.1084/jem.169.3.1021
14. Albina JE, Mills CD, Henry WL Jr, Caldwell MD. Temporal expression of different pathways of 1-arginine metabolism in healing wounds. J Immunol (1990) 144:3877-80.
15. Wu G, Morris SM. Arginine metabolism: nitric oxide and beyond. Biochem J (1998) 336(Pt 1):1-17.
16. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (2000) 164:6166-73. doi:10.4049/jimmunol.164.12.6166
17. Mills CD. Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Crit Rev Immunol (2001) 21:399-425. doi:10.1615/CritRevImmunol.v21.i5.10
18. Mackaness GB. The immunologic basis of acquired cellular resistance. J Exp Med (1964) 120:105-20. doi:10.1084/jem.120.1.105
19. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med (1992) 176:287-92. doi:10.1084/jem.176.1.287
20. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity (2010) 32:593-604. doi:10.1016/j.immuni.2010.05.007
21. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature (2007) 449:419-26. doi:10.1038/nature06175
22. Hume DA. Macrophages as APC and the dendritic cell myth. J Immunol (2008) 181:5829-35. doi:10.4049/jimmunol.181.9.5829
23. Geissmann F, Gordon S, Hume DA, Mowat DA, Randolph GJ. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol (2010) 10:453-60. doi:10.1038/nri2784
24. Erhlich P. Uber den jetzigen Stand der Karzinomforschung. In: Himmelweit F, editor. The Collected Papers of Paul Erlich. (Vol. II), London: Pergamon Press (1957). p. 550-62.
25. Thomas L. Reactions to homologous tissue antigens in relation to hypersensitivity. In: Lawrence HS, editor. Cellular and Humoral Aspects of the Hypersensitive States. New York, NY: Hoeber-Harper (1959). p. 529-32.
26. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res (1970) 13:1-27.
27. Henderson BE. Type B virus and human breast cancer. Cancer (1974) 34(Suppl):1386-9. doi:10.1002/1097-0142(197410)34:8+<1386::AID-CNCR2820340808>3.0.CO;2-5
28. Todaro GJ. Evolution and modes of transmission of RNA tumor viruses. Am J Pathol (1975) 3:590-606.
29. Good RA, Prehn RT, Lawrence HS. Evaluation of the evidence for immune surveillance. In: Landy M, editor. Immune Surveillance. New York, NY: Academic Press (1970). p. 437-518.
30. Dailey MO, Hunter RL. Induction of cell-mediated immunity to chemically modified antigens in guinea pigs. I. Characterization of the immune response to lipid-conjugated protein antigens. J Immunol (1977) 118:957-62.
31. Mills CD. Immunologic and Physical Properties of Cationic and Anionic Derivatives of BSA [PhD Dissertation]. Chicago: University of Chicago (1980).
32. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature (1974) 248:701-2. doi:10.1038/248701a0
33. Glasebrook AL, Fitch FW. T-cell lines which cooperate in generation of specific cytolytic activity. Nature (1979) 278:171-3. doi:10.1038/278171a0
34. Mills CD, North RJ, Dye ES. Mechanisms of anti-tumor action of Corynebacterium parvum. II. Potentiated cytolytic T cell response and its tumor-induced suppression. J Exp Med (1981) 154:621-30. doi:10.1084/jem.154.3.621
35. Mills CD, North RJ. Expression of passively transferred immunity against an established tumor depends on the generation of cytolytic T cells in the recipient. Inhibition by suppressor T cells. J Exp Med (1983) 157:1448-60. doi:10.1084/jem.157.5.1448
36. Lotze MT, Rosenberg SA. The immunologic treatment of cancer. CA Cancer J Clin (1988) 38:68-94. doi:10.3322/canjclin.38.2.68
37. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science (1974) 183:534-6. doi:10.1126/science.183.4124.534
38. Prehn RT. The immune reaction as a stimulator of tumor growth. Science (1972) 176:170-1. doi:10.1126/science.176.4031.170
39. Sznol M, Dutcher JP, Atkins MB, Rayner RA, Margolin KA, Gaynor ER, et al. Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma. Cancer Treat Rev (1989) 16:29-38. doi:10.1016/0305-7372(89)90020-0
40. Schwartz RS. Another look at immune surveillance. N Engl J Med (1975) 293:181-4. doi:10.1056/NEJM197507242930406
41. North RJ, Mackaness GB. Electron microscopal observations on the peritoenal macrophages of normal mice and mice immunised with listereria monocytogenes. II. Structure of macrophages from immune mice and the early cytoplasmic response to the presence of ingested bacteria. Br J Exp Pathol (1963) 44:608-11.
42. Shevach EM, Rosenthal AS. Function of macrophages in antigen recognition by guinea pig T lymphocytes. II. Role of the macrophage in the regulation of genetic control of the immune response. J Exp Med (1973) 138:1213-29. doi:10.1084/jem.138.5.1213
43. Unanue ER. Antigen-presenting function of the macrophage. Annu Rev Immunol (1984) 2:395-428. doi:10.1146/annurev.iy.02.040184.002143
44. Hibbs JB, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun (1988) 157:87-94. doi:10.1016/S0006-291X(88)80015-9
45. Mills CD, Shearer J, Evans R, Caldwell MD. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol (1992) 149:2709-14.
46. MacFarlance AS, Schwacha MG, Eisenstein TK. In vivo blockage of nitric oxide with aminoguanidine inhibits immunosuppression by an attenuated strain of Salmonella typhimurium, potentiates Salmonella infection, and inhibits macrophage and polymorphonuclear leukocyte influx into the spleen. Infect Immun (1999) 67:891-8.
47. Gomes MS, Florido M, Pais TF, Appelberg R. Improved clearance of Mycobacterium avium upon disruption of the inducible nitric oxide synthase gene. J Immunol (1999) 162:6734-9.
48. Mills CD. Molecular basis of "suppressor" macrophages. J Immunol (1991) 146:2719-23.
49. Mills CD, Thomas AC, Lenz LL, Munder M. Macrophage: SHIP of immunity. Front Immunol (2014) 5:620. doi:10.3389/fimmu.2014.00620
50. Medot-Pirenne M, Heilman MJ, Saxena M, McDermott PE, Mills CD. Augementation of antitumor CTL response in vivo by inhibition of suppressor macrophage nitric oxide. J Immunol (1999) 163:5877-82.
51. Stevens RB, Ansite JD, Mills CD, Lokeh A, Rossini TJ, Saxena M, et al. Nitric oxide mediates early dysfunction of rat and mouse islets following transplantation. Transplantation (1996) 61:1740-9. doi:10.1097/00007890-199606270-00014
52. Stevens RB, Sutherland DER, Ansite JD, Saxena M, Rossini TJ, Levay-Young BK, et al. Insulin down regulates the iNOS pathway: nitric oxide as cause and effect of diabetes? J Immunol (1997) 159:5329-35.
53. Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology (2004) 113:427-37. doi:10.1111/j.1365-2567.2004.01984.x
54. Ryan BJ, Nissim A, Winyard PG. Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. Redox Biol (2014) 2:715-24. doi:10.1016/j.redox.2014.05.004
55. Eshleman EM, Lenz LL. Type I interferons in bacterial infections: taming of myeloid cells and possible implications for autoimmunity. Front Immunol (2014) 5:431. doi:10.3389/fimmu.2014.00431
56. Moehle MS, West AB. M1 and M2 immune activation in Parkinson's disease: foe and ally? Neuroscience (2014). doi:10.1016/j.neuroscience.2014.11.018
57. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol (2011) 11:723-37. doi:10.1038/nri3073
58. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 117:195-205. doi:10.1172/JCI29950
59. Li H, Horke S, Förstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis (2014) 237:208-19. doi:10.1016/j.atherosclerosis.2014.09.001
60. Koltsova EK, Hedrick CC, Ley K. Myeloid cells in atherosclerosis: a delicate balance of anti-inflammatory and proinflammatory mechanisms. Curr Opin Lipidol (2013) 5:371-80. doi:10.1097/MOL.0b013e328363d298
61. Heinzel FG, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon γ or interleukin 4 during the resolution or progression of murine leishmaniasis: evidence for expression of distinct helper subsets. J Exp Med (1989) 169:59-72. doi:10.1084/jem.169.1.59
62. Nathan CF, Hibbs JB. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol (1991) 1:65-70. doi:10.1016/0952-7915(91)90079-G
63. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol (1988) 141:2407-12.
64. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, et al. Transforming growth factor type 1 induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A (1987) 84:5788-92. doi:10.1073/pnas.84.16.5788
65. Mao Y, Poschke I, Kiessling R. Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells. J Intern Med (2014) 276:154-70. doi:10.1111/joim.12229
66. Dzik JM. Evolutionary roots of arginase expression and regulation. Front Immunol (2014) 5:544. doi:10.3389/fimmu.2014.00544
67. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol (2006) 177:7303-11. doi:10.4049/jimmunol.177.10.7303
68. Raza S, Barnett MW, Barnett-Itzhaki Z, Amit I, Hume DA, Freeman TC. Analysis of the transcriptional networks underpinning the activation of murine macrophages by inflammatory mediators. J Leukoc Biol (2014) 96:167-83. doi:10.1189/jlb.6HI0313-169R
69. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 25:677-86. doi:10.1016/j.it.2004.09.015
70. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol (2006) 6:1298-307. doi:10.1189/jlb.0406249
71. Fleming BD, Mosser DM. Regulatory macrophages: setting the threshold for therapy. Eur J Immunol (2011) 41:2498-502. doi:10.1002/eji.201141717
72. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 41:14-20. doi:10.1016/j.immuni.2014.06.008
73. Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol (2004) 76:509-13. doi:10.1189/jlb.0504272
74. Mosser DM. The many faces of macrophage activation. J Leukoc Biol (2003) 73:209-21. doi:10.1189/jlb.0602325
75. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci (2014) 105:1-8. doi:10.1111/cas.12314
76. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 41:49-61. doi:10.1016/j.immuni.2014.06.010
77. Tang X, Mo C, Wang Y, Wei D, Xiao H. Anti-tumor strategies to target tumor-associated macrophages. Immunology (2012) 138:92-104. doi:10.1111/imm.12023
78. Weigert A, Brune B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide (2008) 2:95-102. doi:10.1016/j.niox.2008.04.021
79. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 282:2085-8. doi:10.1126/science.282.5396.2085
80. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature (1997) 388:394-7. doi:10.1038/41131
81. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity (1999) 1:443-51. doi:10.1016/S1074-7613(00)80119-3
82. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 23:549-55. doi:10.1016/S1471-4906(02)02302-5
83. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 11:889-96. doi:10.1038/ni.1937
84. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 331:1612-6. doi:10.1126/science.1198443